TY - JOUR
T1 - Cancer-related symptom assessment in Russia
T2 - Validation and utility of the Russian M. D. Anderson Symptom Inventory
AU - Ivanova, Maria O.
AU - Ionova, Tatyana I.
AU - Kalyadina, Svetlana A.
AU - Uspenskaya, Olga S.
AU - Kishtovich, Anton V.
AU - Guo, Hong
AU - Mendoza, Tito R.
AU - Novik, Andrei
AU - Cleeland, Charles S.
AU - Wang, Xin S.
PY - 2005/11
Y1 - 2005/11
N2 - This multicenter cross-sectional study (n = 226) validated the Russian-language M. D. Anderson Symptom Inventory (MDASI-R) in Russian cancer patients with hematological malignancies or solid tumors. The Russian-language Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36-R) also was used for validation. Factor analysis found three underlying constructs for symptom items - general, treatment-related, and affective symptoms - with Cronbach alphas of 0.86, 0.68, and 0.90, respectively. Convergent validity was established by comparing MDASI-R items with SF-36-R subscales. The MDASI-R detected significant differences in symptom severity and interference levels by performance status, supporting known-group validity. The most prevalent symptoms were fatigue, sleep disturbance, pain, sadness, and poor appetite; 53% of the sample reported one to four moderate-to-severe symptoms (≥5 on 0-10 scale). Symptoms interfered most with work and general activity. Medical professionals underestimated the severity of pain, fatigue, and distress. The MDASI-R is valid and reliable for measuring symptom severity and interference in Russian cancer patients.
AB - This multicenter cross-sectional study (n = 226) validated the Russian-language M. D. Anderson Symptom Inventory (MDASI-R) in Russian cancer patients with hematological malignancies or solid tumors. The Russian-language Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36-R) also was used for validation. Factor analysis found three underlying constructs for symptom items - general, treatment-related, and affective symptoms - with Cronbach alphas of 0.86, 0.68, and 0.90, respectively. Convergent validity was established by comparing MDASI-R items with SF-36-R subscales. The MDASI-R detected significant differences in symptom severity and interference levels by performance status, supporting known-group validity. The most prevalent symptoms were fatigue, sleep disturbance, pain, sadness, and poor appetite; 53% of the sample reported one to four moderate-to-severe symptoms (≥5 on 0-10 scale). Symptoms interfered most with work and general activity. Medical professionals underestimated the severity of pain, fatigue, and distress. The MDASI-R is valid and reliable for measuring symptom severity and interference in Russian cancer patients.
KW - Assessment
KW - Cancer-related symptoms
KW - Factor analysis
KW - MDASI
KW - Russia
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=28344456203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28344456203&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2005.04.015
DO - 10.1016/j.jpainsymman.2005.04.015
M3 - Article
C2 - 16310618
AN - SCOPUS:28344456203
SN - 0885-3924
VL - 30
SP - 443
EP - 453
JO - Journal of pain and symptom management
JF - Journal of pain and symptom management
IS - 5
ER -